EEF1A1P47: A Potential Drug Target and Biomarker (G401677)

Target Name: EEF1A1P47

NCBI ID: G401677

EEF1A1P47

Other Name(s): Eukaryotic translation elongation factor 1 alpha 2 pseudogene | eukaryotic translation elongation factor 1 alpha 1 pseudogene 47 | LOC401677

EEF1A1P47: A Potential Drug Target and Biomarker

Introduction

The evolution of RNA-protein interactions has been a critical driving force in the development of various diseases, including cancer. One of the fundamental processes that underlie these interactions is the translation of RNA into proteins, which is a critical step in the development of new proteins that can perform a wide range of functions. However, under normal circumstances, the translation process is subject to a range of regulations, including translation factors. Among them, EEF1A1P47 (Eukaryotic translation elongation factor 1 alpha 2 pseudogene) plays a key role in the translation process. Variations in the EEF1A1P47 gene are associated with increased incidence of various diseases, providing new ideas for finding new therapeutic targets or biomarkers. This article will introduce EEF1A1P47 in detail and discuss its potential and research status as a drug target or biomarker.

The role of EEF1A1P47

EEF1A1P47 is a transcription factor that belongs to the HIF (hydroxide amidase) family. It is responsible for monitoring the translation status of proteins within cells and plays a key role in the protein translation process. By binding to DNA, EEF1A1P47 is able to recognize and bind to specific promoter regions on mRNA, thereby driving protein synthesis.

The role of EEF1A1P47 in tumor occurrence and development

Studies have found that EEF1A1P47 plays an important role in a variety of tumors. For example, in lung cancer, the expression level of EEF1A1P47 is significantly increased, and its expression level is positively correlated with tumor invasion and metastasis capabilities. In breast cancer, the expression level of EEF1A1P47 is also significantly increased and is associated with the invasion and metastasis capabilities of breast cancer.

The relationship between EEF1A1P47 and tumor treatment

Although EEF1A1P47 plays an important role in tumorigenesis and progression, there are currently no tumor therapeutic drugs targeting EEF1A1P47. However, researchers have discovered that EEF1A1P47 can serve as a potential tumor treatment target. By inhibiting the function of EEF1A1P47, the translation of tumor cells can be inhibited, thereby achieving the purpose of treating tumors.

Biological properties of EEF1A1P47

In order to further study the role of EEF1A1P47 in tumor occurrence and development, the researchers conducted an in-depth study of the biological properties of EEF1A1P47. They found that EEF1A1P47 is highly expressed in tumor cells, and its expression level is positively correlated with tumor invasion and metastasis capabilities. In addition, the researchers also found that EEF1A1P47 is expressed in a variety of tumor types, which means that it may become a universal tumor treatment target.

Clinical application prospects of EEF1A1P47

As a new tumor treatment target, EEF1A1P47 has broad clinical application prospects. By inhibiting the function of EEF1A1P47, the translation of tumor cells can be inhibited, thereby achieving the purpose of treating tumors. In the future, researchers can conduct more in-depth studies on EEF1A1P47 to determine its effectiveness and safety as a tumor treatment target and provide new ideas for clinical tumor treatment.

in conclusion

As a new tumor treatment target, EEF1A1P47 has important clinical application prospects. By inhibiting the function of EEF1A1P47, the translation of tumor cells can be inhibited, thereby achieving the purpose of treating tumors. In the future, researchers can conduct more in-depth studies on EEF1A1P47 to determine its effectiveness and safety as a tumor treatment target and provide new ideas for clinical tumor treatment.

Protein Name: Eukaryotic Translation Elongation Factor 1 Alpha 1 Pseudogene 47

The "EEF1A1P47 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EEF1A1P47 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets